From selection hits to clinical leads: progress in aptamer discovery | Zendy

Keith E. Maier | Zendy; Matthew Levy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

From selection hits to clinical leads: progress in aptamer discovery

Author(s) -

Keith E. Maier,

Matthew Levy

Publication year - 2016

Publication title -

molecular therapy — methods and clinical development

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.285

H-Index - 32

ISSN - 2329-0501

DOI - 10.1038/mtm.2016.14

Subject(s) - aptamer , food and drug administration , computational biology , drug discovery , clinical trial , biology , pharmacology , medicine , microbiology and biotechnology , computer science , bioinformatics , genetics

Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research